Fulltext

Probiotic Bifidobacterium lactis Probio-M8 treated and prevented acute RTI, reduced antibiotic use and hospital stay in hospitalized young children: a randomized, double-blind, placebo-controlled study

Mageswary MU 1 , Ang XY 1 , Lee BK 1 , Chung YF 1 , Azhar SNA 2 , Hamid IJA 3 Show all authors , Bakar HA 1 , Roslan NS 2 , Liu X 4 , Kang X 5 , Dai L 5 , Sreenivasan S 6 , Taib F 7 , Zhang H 8 , Liong MT 9

Affiliations 

  • 1 School of Industrial Technology, Universiti Sains Malaysia, 11800, Penang, Malaysia
  • 2 School of Medical Sciences, Universiti Sains Malaysia, 16150, Kelantan, Malaysia
  • 3 Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Penang, Malaysia
  • 4 Beijing Scitop Biotech Co., Ltd., Beijing, 101407, China
  • 5 Inner Mongolia Mengniu Dairy (Group) Co. Ltd., Shengle Economic Zone, Helingeer, Huhhot, 011500, Inner Mongolia, China
  • 6 Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, 11800, Penang, Malaysia
  • 7 School of Medical Sciences, Universiti Sains Malaysia, 16150, Kelantan, Malaysia. [email protected]
  • 8 Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, 010018, Inner Mongolia, China. [email protected]
  • 9 School of Industrial Technology, Universiti Sains Malaysia, 11800, Penang, Malaysia. [email protected]
Eur J Nutr, 2021 Nov 26.
PMID: 34825264 DOI: 10.1007/s00394-021-02689-8

Abstract

PURPOSE: The development of probiotics has seen tremendous growth over the years, with health benefits ranging from gut health to respiratory. We thus aimed to investigate the effects of probiotic Bifidobacterium lactis Probio-M8 (2 × 1010 log CFU/day) against acute respiratory tract infections (RTI), use of antibiotics, hospitalization period and elucidate the possible mechanisms of action in hospitalized young children.

METHOD: A prospective, randomized, double-blind and placebo-controlled study was performed in RTI-hospitalized children. Patients were randomized to either the probiotic (n = 60, mean age 13.81 ± 0.90 months) or placebo (n = 60, mean age 12.11 ± 0.73 months) which were administered upon admission, continued during hospitalization and 4-week post-discharged. RTI and gut health parameters were assessed at these time points using validated questionnaires while concentrations of inflammatory cytokines were assessed via oral swabs.

RESULTS: Probio-M8 reduced the duration of nasal, pharyngeal and general flu-like symptoms compared to the placebo during the hospitalization period and 4-week post-discharged (P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications